Semaglutide vs Tesofensine

These sit in different classes. Semaglutide is a GLP-1 / incretin agonist; Tesofensine is a metabolic compound. They get compared because of where they overlap, not because they are interchangeable.

The overlap is appetite control and fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — Semaglutide rates 4/5 for appetite control and Tesofensine rates 5/5. Outside that overlap only Semaglutide goes further, carrying weight for metabolic health; Tesofensine's declared goals stop at the overlap.

Semaglutide sits one step firmer: an approved label and the randomized trial package behind it. Tesofensine has approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

Semaglutide is a subcutaneous injection and taken by mouth; Tesofensine is taken by mouth. Neither one forces you onto a needle.

Half-lives are close — 7 days for Semaglutide, 9.2 days for Tesofensine — yet the schedules are not: once a week versus once daily. Similar clearance and different dosing means the difference comes from protocol convention, not from how fast either one leaves you.

One of these has an end date and the other does not: Semaglutide runs no fixed cycle, Tesofensine runs 24 weeks. An open-ended compound is a standing commitment, not a course you finish. Semaglutide also escalates through a titration schedule rather than holding one dose, so its first weeks are not its steady state.

The contraindication lists are not the same: Semaglutide flags MTC or MEN2 history, pancreatitis history, and thyroid disease, which Tesofensine does not; Tesofensine flags under 18, which Semaglutide does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

Semaglutide is rated intermediate here and Tesofensine advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.